Various carrier system(s)-mediated genetic vaccination strategies against malaria

Expert Review of Vaccines

Volumn 7, Issue 4, 2008, Pages 499-520

  Tyagi, Rajeev K ^a   Sharma, Pradeep Kumar ^b   Vyas, Suresh P ^c   Mehta, Abhinav ^c  

^a INSTITUT PASTEUR   (France)

^b CH CHARAN SINGH UNIVERSITY   (India)

^c DR H S GOUR UNIVERSITY   (India)

Author keywords

Adjuvant; Cationic lipid; Hemagglutinin; Immunogenicity; Immunopotentiating reconstituted influenza virosome; Microsphere; pH sensitive liposome; Subunit vaccine; Transcription activator protein; Transfection; Virosome

Indexed keywords

ANTIGEN; CIRCUMSPOROZOITE PROTEIN; CS 102; DIPHTHERIA TETANUS TOXOID; DNA VACCINE; DOXORUBICIN; ERYTHROCYTE ANTIGEN; GLUTAMIC ACID; LIPOPLEX; LIPOSOME; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MICROSPHERE; NUCLEIC ACID; PLASMID DNA; POLY(ORTHO ESTER); POLYMER; RTS S VACCINE; SERINE; VACCINE; VIROSOME; VIROSOME VACCINE;

BLOOD; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; GENE TRANSFER; GENETIC IMMUNIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; LIFE CYCLE; MALARIA; MEMBRANE MICROPARTICLE; NONHUMAN; PARASITOLOGY; PLASMODIUM; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

HUMANS; LIPOSOMES; MALARIA; MALARIA VACCINES; MICROSPHERES; NANOPARTICLES; VACCINATION; VACCINES, DNA; VIROSOMES;

EID: 43249084213     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.4.499     Document Type: Review

References (161)

1. WHO. Tropical diseases in media spotlight. TDR News 31, 3 (1990).
2. White NJ. Drug resistance in malaria. Br. Med. Bull. 54(3), 703-715 (1998).
3. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop. 95(3), 298-304 (2005).
4. Curtis CF. Should the use of DDT be revived for malaria vector control? Biomedica 22(4), 455-461 (2002).
5. Malkin E, Dubovsky F, Moree M. Progress towards the development of malaria vaccines. Trends Parasitol. 22(7), 292-295 (2006).
6. Day KP, Marsh K. Naturally acquired immunity to Plasmodium falciparum. Immunol. Today 12(3), A68-A71 (1991).
7. Smith TA, Leuenberger R, Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol. 17(3), 145-149 (2001).
8. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45(3), 297-308 (1991).
9. Nussenbzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoite of Plasmodium berghei. Nature 216, 160-162 (1967).
10. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite induced falciparum malaria. Am. J. Med. Sci. 266(6), 398-403 (1973).
11. Clyde DF, McCarthy VC, Miller RM, Vanderberg JP. Specificity of protection of man immunized against sporozoite induced falciparum malaria. Am. J. Med. Sci. 266(3), 169-177 (1973).
12. Clyde DF, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. J. Trop. Med. Hyg. 24(3), 397-401 (1975).
13. Gwadz RW, Cochrane AH, Nussenbzweig V, Nussenbzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowleski and characterization of surface antigens of these parasites. Bull. World Health Organ. 57(1), 165-173 (1979).
14. Targett GA. Malaria vaccines 1985-2005: a full circle? Trends Parasitol. 21(11), 499-503 (2005).
15. Doolan DL, Hoffman SL. DNA based vaccines against malaria: status and promise of the multistage malaria. DNA Vaccine Operation. Int. J. Parasitol. 31, 753-762 (2006). • Comprehensive evaluation and studies of the MustDo Vaccine Initiative, providing particular insights into the DNA-based vaccines.
16. Dubovsky F, Rabinovich NR. Malaria vaccines. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA 1283-1289 (2004).
17. Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine 25(9), 1567-1580 (2007). • Very informative and attempts to summarizes state-of-the-art malaria vaccine development.
18. Tuikue Ndam NG, Salanti A, Le-Hesran JY, Cottrell G, Fievet N, Turner L. Dynamics of anti-VAR2CSA immunoglobulin G response in a cohort of Senegalese pregnant women. J. Infect. Dis. 193(5), 713-720 (2006).
19. Fried M, Domingo GJ, Gowda CD, Mutabingwa TK, Duffy PE. Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. Exp. Parasitol. 113(1), 36-42 (2006).
20. Herrera MA, Herrera S. Plasmodium vivax malaria vaccine development. Mol. Immunol. 38, 443-455 (2001).
21. McGregor IE. The passive transfer of human malarial immunity. Am. J. Trop. Med. Hyg. 13, 237-239 (1964).
22. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 49(2), 166-173 (1993).
23. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185(8), 1155-1164 (2002).
24. Mendis KN, Munesinghe YD, de Silva YN, Keragalla I, Carter R. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect. Immun. 55, 369-372 (1987).
25. Hisaeda H, Stowers AW, Tsuboi T et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68, 6618-6623 (2000).
26. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6(1), 21-32 (2006).
27. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206(Pt 21), 3803-3808 (2003).
28. Good MF. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 21(1), 29-34 (2005).
29. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433(7022), 164-167 (2005).
30. Hill AV, Allsopp CE, Kwiatkowski D. Common west African HLA antigens are associated with protection from severe malaria. Nature 352, 595-600 (1991).
31. + T cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10(4), 406-410 (2004).
32. Nardin EH, Nussenzweig V, Nussenzweig RS. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156, 20-30 (1982).
33. Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 11, 687-727 (1993).
34. Clyde DF, McCarthy VC, Miller MR, Woodward WF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24, 397-401 (1975).
35. Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. World Health Organ. 57, 261-265 (1979).
36. Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F, Tonegawa S. γ δ T cells contribute to immunity against the liver stages of malaria in α β T-cell-deficient mice. Proc. Natl Acad. Sci. USA 91(1), 345-349 (1994).
37. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11(4), 412-419 (1999).
38. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS. Preerythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41(1-3), 397-402 (1999).
39. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T. α-galactosylceramide activated V α 14 natural killer T cells mediate protection against murine malaria. Proc. Natl Acad. Sci. USA 97(15), 8461-8466 (2000).
40. + T cells producing IFN-γ. J. Immunol. 171(12), 6961-6967 (2003).
41. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite induced falciparum malaria. Am. J. Med. Sci. 266, 169-177 (1973).
42. Edelman R, Hoffman SL, Davis JR. Long-term persistence of sterile immunity in a volunteer immunized with x-irradiated Plasmodium falciparum sporozoites. J. Infect. Dis. 168, 1066-1070 (1993).
43. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2), 86-91 (1997).
44. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183(4), 640-647 (2001).
45. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178(4), 1139-1144 (1998).
46. Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23, 4148-4157 (2005).
47. Roggero MA, Filippi B, Church P, Hoffman SL, Blum-Tirouvanziam U, Lopez JA. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol. Immunol. 32(17/18), 1301-1309 (1995).
48. Prato S, Maxwell T, Pinzon-Charry A, Schmidt CW, Corradin G, Lopez JA. MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. Eur. J. Immunol. 35(3), 681-689 (2005).
49. Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes. J. Infect. Dis. 182(5), 1486-1496 (2000).
50. Kublin JG, Lowitt MH, Hamilton RG, Oliveira GA, Nardin EH, Nussenzweig RS. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCSMAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20(13/14), 1853-1861 (2002).
51. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A. Safety, immunogenicity and efficacy of a preerythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23(7), 857-864 (2005).
52. +-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J. Virol. 77(21), 11859-11866 (2003).
53. Tsuji M, Bergmann CC, Takita-Sonoda Y et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72(8), 6907-6910 (1998).
54. Bruña-Romero O, González-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl Acad. Sci. USA 98(20), 11491-11496 (2001).
55. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J. Safety profile of the viral vectors of attenuated fowl pox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin. Infect. Dis. 42(8), 1102-1110 (2006).
56. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24(15), 3026-3034 (2006).
57. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18(18), 1893-1901 (2000).
58. Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther. 8(13), 1011-1023 (2001).
59. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282(5388), 476-480 (1998).
60. +) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl Acad. Sci. USA 98(19), 10817-10822 (2001).
61. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143 (2004).
62. Hill AV, Reece W, Gothard P, Moorthy V, Roberts M, Flanagan K. DNA-based vaccines for malaria: a heterologous prime-boost immunization strategy. Dev. Biol. (Basel) 104, 171-179 (2000).
63. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P. A randomized, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1(2), e33 (2004).
64. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74(10), 5933-5942 (2006). • DNA prime-boost vaccination (with vaccinia Ankara vaccine) showing the protection for thrombospondin-related adhesive protein for Plasmodium falciparum.
65. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102(13), 4836-4841 (2005).
66. Bejon P, Mwacharo J, Kai OK et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccina virus Ankara encoding the pre-erythrocytic antigen METRAP in 1-6 year old children in a malaria endemic area. Vaccine 24(22), 4709-4715 (2006).
67. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol. 17, 219-223 (2001).
68. Daubersies P, Thomas AW, Millet P et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. 6, 1258-1263 (2000).
69. Barnes DA, Wollish W, Nelson RG, Leech JH, Petersen C. Plasmodium falciparum: D260, an intra-erythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins. Exp. Parasitol. 81, 79-89 (1995).
70. Patarroyo G, Franco L, Amador R, Murillo LA, Rocha CL, Rojas M. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 10(3), 175-178 (1992).
71. Alonso PL, Smith TA, Armstrong-Schellenberg JR, Kitua AY, Masanja H, Hayes R. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J. Infect. Dis. 174(2), 367-372 (1996).
72. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H. Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344(8931), 1175-1181 (1994).
73. Egan AF, Morris J, Barnish G. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173, 765-769 (1996).
74. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21, 133-139 (1999).
75. O'Donnell RA, de Koning-Ward TF, Burt RA. Antibodies against merozoite surface protein (msp)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193, 1403-1412 (2001).
76. Holder AA, Guevara Patino JA, Uthaipibull C. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parasitologia 41, 409-414 (1999).
77. Keitel WA, Kester KE, Atmar RL. Phase I trial of two recombinant vaccines containing the 19 kDa carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18, 531-539 (1999).
78. Del Portillo HA, Longacre S, Khouri E, David PH. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc. Natl Acad. Sci. USA 88, 4030-4034 (1991).
79. Putaporntip C, Jongwutiwes S, Tanabe K, Thaithong S. Interallelic recombinant in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates. Mol. Biochem. Parasitol. 84, 49-56 (1997).
80. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185(6), 820-827 (2002).
81. Chitarra V, Holm I, Bentley GA, Petres S, Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol. Cell 3(4), 457-464 (1999).
82. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64(1), 253-261 (1996).
83. Daly TM, Long CA. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155(1), 236-243 (1995).
84. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J. Immunol. 154(11), 6022-6030 (1995).
85. Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22(29-30), 3831-3840 (2004).
86. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25(1), 176-184 (2007).
87. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am. J. Trop. Med. Hyg. 73(5 Suppl.), 16-24 (2005).
88. Kocken CH, Dubbeld MA, Van Der Wel A, Pronk JT, Waters AP, Langermans JA. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect. Immun. 67(1), 43-49 (1999).
89. Kocken CH, Narum DL, Massougbodji A et al. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol. Biochem. Parasitol. 109(2), 147-156 (2000).
90. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23(23), 3076-3083 (2005).
91. Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity and antibody-mediated inhibition of parasite growth in vitro. J. Immunol. 172(10), 6167-6174 (2004).
92. Zhang D, Pan W. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Infect. Immun. 73(10), 6530-6536 (2005).
93. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172(6), 1633-1641 (1990).
94. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 60(4), 1473-1481 (1992).
95. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibodydependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182(2), 409-418 (1995).
96. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73(12), 8017-8126 (2005).
97. Druilhe P, Spertini F, Soesoe D et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2(11), e344 (2005).
98. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J. Infect. Dis. 181(3), 1202-1205 (2000).
99. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect. Immun. 66(1), 11-17 (1998).
100. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect. Immun. 72(1), 247-252 (2004).
101. Li J, Mitamura T, Fox BA, Bzik DJ, Horii T. Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment. Parasitol. Int. 51(4), 343-352 (2002).
102. Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, Egwang TG. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am. J. Trop. Med. Hyg. 74(2), 191-197 (2006).
103. Inselburg J, Bathurst IC, Kansopon J, Barr PJ, Rossan R. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect. Immun. 61(5), 2048-2052 (1993).
104. Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J. Infect. Dis. 183(2), 303-312 (2001).
105. Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am. J. Trop. Med. Hyg. 73(5 Suppl.), 25-31 (2005).
106. Kaslow DC. Transmission-blocking vaccine. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Hoffman SL (Ed.). American Society for Microbiology, Washington, DC, USA 181-227 (1996).
107. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria transmission-blocking vaccines - how can their development be supported? Nat. Med. 6(3), 241-244 (2000).
108. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68(12), 6618-6623 (2000).
109. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23(24), 3131-3138 (2005).
110. Bustamante PJ, Woodruff DC, Oh J, Keister DB, Muratova O, Williamson KC. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol. 22(8), 373-380 (2000).
111. Becker DG, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12(6), 807-815 (2000). • Reveals the adjuvant role of monophosphoryl lipid A and mentions the significant antigen presentation.
112. Aucouturier J, Dupuis L, Ganne V. Adjuvant designed for veterinary and human vaccines. Vaccine 19, 2666-2672 (2001).
113. Bangham AD, Standish MM, Miller N. Cation permeability of phospholipid model membranes: effect of narcotics. Nature 208, 1295-1297 (1965).
114. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 252, 252 (1974).
115. Rosenkrands I, Agger ME, Olsen WA et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect. Immun. 73(9), 5817-5826 (2005). •• Mentions the particular insights of the liposome formulation and its potent role in a Th1 adjuvant system.
116. Owais M, Gupta CM. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 267, 3946-3956 (2000). •• Infers the cytosolic delivery of macromolecules by liposomes, advocating the flexibility and versatility of the carrier system.
117. Vyas SP, Jadon RS, Goyal AK et al. pH sensitive liposomes enhances immunogenicity of 19 kDa carboxyl-terminal fragment of Plasmodium falciparum. Int. J. Pharm. Sci. Nanotech. (2007) (In press).
118. Tiwari S, Goyal AK, Khatri K, Gupta PN, Mishra N, Vyas SP. Gel core liposomes: an advanced carrier for improved vaccine delivery. J. Microencapsulation (2007) (In press). • Opens new venues for the improvement of the vaccine delivery through gel-core liposomes, which are considered an advanced carrier system.
119. Meykadeh N, Mirmohammadsadegh A, Wang Z, Schakarjan EB, Hengge UR. Topical application of plasmid DNA to mouse and human skin. J. Mol. Med. 83, 897-903 (2005).
120. Choi MJ, Maibach HI. Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol. Appl. Skin Physiol. 16, 271-282 (2003). • Shows the possibility of the topical immunization of DNA.
121. Singh RP, Singh P, Mishra V, Prabakaran D, Vyas SP. Vesicular systems for non-invasive topical immunization: rationale and prospects. Ind. J. Pharmacol. 34, 301-310 (2002).
122. Bramson J, Dayball K, Evelegh C, Wan YH, Page D, Smith A. Enabling topical immunization via microporation: a novel method for pain free and needle free delivery of adenovirus-based vaccines. Gene Ther. 10, 251-260 (2003).
123. Toussignant JD, Gates AL, Ingram LA et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther. 11, 2493-2513 (2000).
124. Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum. Gene Ther. 8, 1585-1594 (1997).
125. Li S, Wu PS, Whitmore M et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipid vectors. Am. J. Physiol. 276, L796-L804 (1999).
126. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17, 521-525 (2000).
127. Kanter RD, Monshouwer M, Meijer DK, Groothuis GM. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr. Drug Metab. 1, 39-59 (2002).
128. Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection. AAPS J. 6(4), 1-10 (2004).
129. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Sternberg BP, D'Souza GMG. Cell transfection in vitro and in vivo with non-toxic TAT peptide-liposome-DNA complexes. Proc. Natl Acad. Sci. USA 100(4), 1972-1977 (2003).
130. Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90, 2491-2495 (1992).
131. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines 2, 189-196 (2003).
132. Gluck R, Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 21, 611-615 (2003).
133. Bungener L, Huckriede A, Wilschut J, Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs. Biosci. Rep. 22(2), 323-338 (2002). •• Comparison of virosomes with other lipid-based delivery/adjuvant systems.
134. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 21, 921-924 (2003).
135. Zurbriggen R, Gluck R. Immunogenicity of IRIV versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11-12), 1301-1305 (1999).
136. Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39(1), 3-18 (2000). •• Analytical methods for the characterization of virosomal vaccines.
137. Fehr T, Bachmann MF, Bucher E et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J. Exp. Med. 185(10), 1721-1723 (1997).
138. Huckriede A, Bungener L, ter Veer W et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 21, 925-931 (2003).
139. Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. 25, 3445-3451 (1995).
140. + T cell activation. Vaccine 22, 714-723 (2004).
141. Mueller MS, Renard A, Boato F et al. Induction of parasite growth inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 71, 4749-4758 (2003).
142. Hunziker IP, Grabscheid B, Zurbriggen R, Gluck R, Pichler WJ, Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int. Immunol. 14, 615-626 (2002).
143. Cusi MG, Zurbriggen R, Correale P et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine 20, 3436-3442 (2002).
144. Correale P, Cusi MG, Sabatino M et al. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer 37, 2097-2103 (2001). • DNA-encoded antigen delivery by virosomes induces systemic cellular immune response against a cancer antigen.
145. Cusi MG, Fischer S, Sedlmeier R et al. Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. Virus Res. 74, 133-137 (2001).
146. Scardino A, Correale P, Firat H et al. In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. Br. J. Cancer 89, 199-205 (2003).
147. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11, 965-969 (1993).
148. O'Hagan DT, Rafferty D, Wharton S, Illum L. Intravaginal immunization in sheep using a bio-adhesive microsphere antigen delivery system. Vaccine 11, 660-664 (1993).
149. Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell
150. Mataa E, Carcaboso AM, Hernández RM, Igartua M, Corradin G, Pedraz JL. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 25, 877-885 (2007). • Comparative study showing the potent adjuvant attribute of the microparticles for merozoite surface protein-2 long synthetic peptide.
151. Carcaboso AM, Hernández RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22, 1423-1432 (2004).
152. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 50, 129-146 (2000).
153. Thomasin C, Corradin G, Men Y, Merkle HP, Gander B, Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 41, 131-145 (1996).
154. Men Y, Tamber H, Audran R, Gander B, Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 15, 1405-1412 (1997).
155. Walter E, Dreher D, Kok M et al. Hydrophilic poly (D,L-lactide-co-gylcolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells, J. Control. Release 76, 149-168 (2001).
156. Prior S, Gander B, Blarer N et al. In vitro phagocytosis and monocyte-macrophage activation with poly (lactide) and poly (lactide-co- glycolide) microspheres. Eur. J. Pharm. Sci. 15, 197-207 (2002).
157. Lunsford L, McKeever U, Eckstein V, Hedley ML. Tissue distribution and persistence in mice of plasmid DNA encapsulated in PLGA-based microsphere delivery vehicle. J. Drug Target. 8, 39-50 (2000).
158. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly (D,L-lactic-coglycolic acid) microspheres by antigenpresenting cells in vivo. J. Biomed. Mater. Res. 60, 480-486 (2002).
159. Jilek S, Ulrich M, Merkle HP, Walter E. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm. Res. 21, 1240-1247 (2004).
160. Banchereau J, Briere B, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000). • Authoritative review of dendritic cell biology.
161. Hagan DT, Singh M, Ulmer JB. Microparticle based technologies for vaccines. Methods 40, 10-19 (2006). •• Microparticle-based vaccine technology has been well defined, revealing the advantages of polymeric microparticles for delivery.